Intratect

Human Normal Immunoglobulin, the active ingredient in Intratect, is an immunoglobulin presented as a solution for injection for intravenous use. It provides passive immunity and is indicated for primary and secondary immunodeficiency diseases, Kawasaki disease, and immune thrombocytopenic purpura, helping to reduce infections and modulate immune responses in affected patients.

GNH USA supplies Intratect as a licensed, GDP‑compliant international pharmaceutical supplier originating from the European Union market and serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide across multiple continents.

Intratect is used in immune‑mediated conditions to replace deficient antibodies and modulate immune activity.

Primary immunodeficiency diseases: restores IgG levels to reduce infection frequency. Secondary immunodeficiency (e.g., chemotherapy, HIV): provides passive immunity to support immune function during treatment. Kawasaki disease: reduces inflammation and lowers risk of coronary artery complications. Immune thrombocytopenic purpura (ITP): increases platelet counts by modulating autoimmune destruction. Idiopathic thrombocytopenic purpura: helps raise platelet levels through immune regulation.

Intratect may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache - Fever - Chills - Nausea - Fatigue - Infusion‑related reactions (e.g., flushing, erythema)

Serious or Rare Side Effects: - Anaphylaxis or severe allergic reactions - Thromboembolic events (e.g., deep vein thrombosis) - Acute renal dysfunction - Aseptic meningitis - Hemolysis - Severe thrombocytopenia

Before initiating Intratect therapy, clinicians should consider several safety precautions to minimize risks.

Assess IgG levels: determine baseline immunoglobulin concentrations to guide dosing. Monitor for infections: watch for new or worsening infections during treatment. Screen for allergic history: identify prior reactions to blood products or immunoglobulins. Adjust infusion rate: reduce speed if infusion‑related reactions occur. Avoid concurrent blood products: unless clinically necessary, to prevent overload. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Intratect can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Live attenuated vaccines: may be neutralized, reducing vaccine effectiveness. - High‑dose aspirin or other NSAIDs: increased risk of bleeding complications. - Concurrent immunoglobulin products: risk of volume overload and duplicate therapy. - Rituximab or other B‑cell depleting agents: may diminish Intratect efficacy. - Anticoagulants (e.g., warfarin): potential for enhanced anticoagulant effect.

Moderate Interactions (Monitor Closely): - Diuretics: may increase risk of renal stress during infusion. - ACE inhibitors: possible hypotension during rapid infusion. - Corticosteroids: may mask signs of infection. - Antibiotics with nephrotoxic potential: monitor renal function.